STRATA Skin Sciences Announces Independent Study Published in the Journal of The European Academy of Dermatology and Venereology
Vitiligo Repigmentation Achieved in Five Treatments with XTRAC® Excimer Laser
The study results demonstrated that patients with refractory vitiligo achieved satisfactory repigmentation in five treatments, including those who were previously unresponsive to conventional treatments such as topical steroids, excimer light and narrowband UVB light. These patients were treated under a minimal blistering dose protocol using the XTRAC excimer laser, which provided better therapeutic effects with fewer treatments as compared to other UVB phototherapies. The study attributed better patient outcomes to XTRAC’s higher irradiation rate as compared to other available UVB phototherapies. In addition, the XTRAC treatments were well tolerated, and the use of a minimal blistering dose was shown to potentially reduce the number of treatment sessions required, thereby lessening the burden on patients and medical staff.
“We are delighted to see independent studies performed that continue to validate and highlight the efficacy of our XTRAC excimer laser in treating dermatologic diseases,” said
Reference - Noborio, R., Nomura, Y., Nakamura, M., Nishida, E., Kiyohara, T., Tanizaki, H. and Morita, A. (2021), Efficacy of 308‐nm excimer laser treatment for refractory vitiligo: a case series of treatment based on the minimal blistering dose. J Eur Acad Dermatol Venereol.
About
The Company’s proprietary XTRAC® excimer laser delivers a highly targeted therapeutic beam of UVB light to treat psoriasis, vitiligo, eczema, atopic dermatitis and leukoderma, diseases which impact over 31 million patients in
STRATA’s unique business model leverages targeted Direct to Consumer (DTC) advertising to generate awareness and utilizes its in-house call center and insurance advocacy teams to increase volume for the Company’s partner dermatology clinics.
The XTRAC business has used this proven DTC model to grow its domestic dermatology partner network to over 832 clinics, with a worldwide installed base of over 2,300 devices. The Company is able to offer 90% of DTC patients an introduction to physicians prescribing a reimbursable solution, using XTRAC, within a 10-mile radius of their house. The Company is a leader in dermatology in-clinic business generation for its partners.
The Company has now introduced its Home by XTRAC™ business, leveraging in-house resources; including DTC advertising, in-house call center and its insurance reimbursement team to provide an at-home, insurance-reimbursed treatment option for patients with certain skin diseases that do not qualify for in-office treatments.
Safe Harbor
This press release includes “forward-looking statements” within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to the Company’s plans, objectives, expectations and intentions and may contain words such as “will,” “may,” “seeks,” and “expects,” that suggest future events or trends. These statements, the Company’s ability to generate the growth in its core business, the Company’s ability to develop social media marketing campaigns, and the Company’s ability to build a leading franchise in dermatology and aesthetics, the Company’s ability to develop a business for home-based treatment of skin diseases, are based on the Company’s current expectations and are inherently subject to significant uncertainties and changes in circumstances. Actual results may differ materially from the Company’s expectations due to financial, economic, business, competitive, market, regulatory, adverse market conditions or supply chain interruptions resulting from the corona virus and political factors or conditions affecting the Company and the medical device industry in general, future responses to and effects of COVID-19 pandemic, as well as more specific risks and uncertainties set forth in the Company’s SEC reports on Forms 10-Q and 10-
Investor Contacts:
(415) 937-5404 | ||
ir@strataskin.com |
Source: STRATA Skin Sciences, Inc.